Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16237160 | 0.93 | KCNH2 (0.35) | LTA4HFFAR4 | |
| SCHEMBL16237619 | 0.85 | CYP2D6 (0.36) | LTA4HCYP2D6CCR3 | |
| SCHEMBL16237808 | 0.85 | CYP2D6 (0.36) | LTA4HCYP2D6CCR3 | |
| SCHEMBL16237492 | 0.79 | KCNH2 (0.42) | CYP2D6CCR3 | |
| SCHEMBL16237458 | 0.78 | KCNH2 (0.35) | CYP2D6CCR3 | |
| SCHEMBL16237122 | 0.78 | CYP2D6 (0.35) | LTA4HCYP2D6CCR3 | |
| SCHEMBL16237558 | 0.77 | CYP2D6 (0.38) | LTA4HCYP2D6CCR3 | |
| SCHEMBL16236918 | 0.76 | CYP2D6 (0.38) | LTA4HCYP2D6CCR3 | |
| SCHEMBL16237555 | 0.75 | CYP2D6 (0.41) | LTA4HCYP2D6CCR3ADORA2AADORA1 | |
| SCHEMBL16240636 | 0.75 | KCNH2 (0.43) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997032-A1 | 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-03-23 | — | — | EP | claimed |
| WO-2014184328-A1 | 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-20 | — | — | WO | claimed |
| EP-2997032-A1 | 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| WO-2014184328-A1 | 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-20 | — | — | WO | disclosed |